Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bridgebio Pharma Inc.
Headquarters: Palo Alto, CA, United States of America
Website: http://bridgebio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Neil Kumar, PhD
Number Of Employees: 730
Enterprise Value: $6,644,805,955
PE Ratio: -12.78
Exchange/Ticker 1: NASDAQ:BBIO
Exchange/Ticker 2: N/A
Latest Market Cap: $6,922,879,488
BioCentury | Mar 19, 2025
Management Tracks
CFO Brian Stephenson exits Bridgebio
Plus: CEO Edward Kayne steps down at Stoke, and updates from Collegium, Pyxis, Recursion and Tonix
BioCentury | Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
BioCentury | Feb 28, 2025
Finance
Eikon draws $350M private round, holding off on public markets
Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising
BioCentury | Feb 13, 2025
Emerging Company Profile
Unnatural: Expanding the macrocyclic peptide chemical space
Company applying small molecule optimization techniques to peptides with a robotic synthesis platform
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | Dec 11, 2024
Data Byte
November’s FDA approvals include Autolus’ CD19 CAR T
Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
BioCentury | Oct 31, 2024
Data Byte
Seven PDUFA dates on FDA’s November calendar
Upcoming decisions include BridgeBio’s
Items per page:
1 - 10 of 131